Studies related to Liver Enzymes and Tribulus terrestris

Tribulus Terrestris Versus Placebo In The Treatment Of Erectile Dysfunction And Lower Urinary Tract Symptoms In Patients With Late-onset Hypogonadism: A Placebo-controlled Study

Effect Increase
Values AST increased from 26.54 to 27.77 in the intervention group and was unchanged in the placebo group. ALT increased from 24.09 to 24.66 (not significant) in the intervention group and decreased from 19.88 to 19.50 in the placebo group (not significant).
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 70
Sex Male
Age Range 30-44, 45-64, 65+
Notes for this study:
70 men with erectile dysfunction and partial androgen deficiency took either 750 mg/d of Tribulus (divided into 3 equal doses) or placebo for 3 months. Participants in the Tribulus group saw a significant increase in aspartate transaminase, total testosterone, and erectile function relative to baseline. There was a significant increase in prostate-specific antigen and no significant change in alanine transaminase or the international prostate symptom score. There were no between-group comparisons, however, the placebo group saw no significant changes in any parameter.